SK Bioscience will complete major facilities in Songdo
By Chon, Seung-Hyun | translator Choi HeeYoung
21.12.28 06:19:12
가나다라
0
Songdo's leading bio companies such as Samsung Biologics, Celltrion, and Celltrion Healthcare
All of the 1st to 4th place in pharmaceutical bio market capitalization moved into Songdo, and its performance is superior
SK Bioscience, the third-largest pharmaceutical bio company in market capitalization, will build a new construction in Songdo, Incheon. It will invest 300 billion won by 2024 to build a new factory and laboratory. Along with Samsung Biologics, Celltrion, and Celltrion Healthcare, the first to fourth place in the pharmaceutical bio market will gather in Songdo side by side.
◆SK Bioscience will complete the facility in Songdo in 2024 and invested 300 billion won
SK Bioscience announced on the 27th that it has signed a land sale contract with the Incheon Free Economic Zone Authority. The plan calls for the construction of a global R&PD (Research & Process Development) center on a 34,414�
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)